

Q1: Quarterly Industry Update

AS OF March 31, 2024



Hemp Industry Summary

COGENT VALUATION identified **Hemp** publicly traded companies, IPOs, and recent M&A transactions within the Hemp industry, which provides a basis for market and transaction pricing that can be used by your firm in estimating market sentiment and its impact on your firm's value. Over the last year since March 31, 2023, the median 52-week share price return of the Hemp industry decreased from -65.3% to -50.5%, and the median YTD return increased from -44.2% to -41.9%. Between March 31, 2023 and March 31, 2024, the median EV/Revenue multiple decreased from 35.9 to 25.35 and the median EV/EBITDA multiple decreased from 55.8 to 47.47. The median price-to-earnings multiple increased from 27.23 to 36.42 and the median EV/Gross Profit multiple decreased from .7 to -3.40 over the same period. The median MVIC/Earnings multiple increased from 23.2 to 26.96% The median Price/Revenue increased from -4.94 to -4.65 over the same period.

Public Company Key Statistics

Median 52-Week Return	Median 3-Year CAGR Return	Median EV/Revenue Multiple	Median EV/EBITDA Multiple
-50.5%	-41.9%	25.35x	47.47x
Median Price/Earnings Multiple	Median EV/Gross Profit Multiple	Median MVIC/Earnings Multiple	Median Price/Revenue Multiple
36.42x	-3.40x	26.96x	-4.44x

Comparable Public Company Market Metrics as of March 31, 2024

	2024	1 Year	2 Year	Revenues	Gross Profit	Net Income	GP Margin	NI Margin	P/Rev.	P/GP
22nd Century Group, Inc.	-11.1%	-32.4%	130.0%	\$25.23	\$0.46	-278.3%	1.8%	-11.0%	12.28x	679.82x
420 Property Management, Inc.	-25.0%	29.7%	141.2%	\$0.05	\$0.05	-831.2%	100.0%	-16624.9%	0.01x	0.01x
Acacia Diversified Holdings, Inc.	-71.2%	-31.3%	-21.8%	\$0.27	\$0.11	-198.4%	42.5%	-738.6%	13.71x	32.28x
Algae Dynamics Corp.	15.0%	-52.7%	87.8%	N/A	N/A	-262.3%	N/A	N/A	N/A	N/A
Artelo Biosciences, Inc.	N/A	-59.6%	30.3%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Aurora Cannabis Inc.	-35.1%	19.4%	123.6%	\$87.28	\$50.14	-5249.8%	57.4%	-60.1%	56.82x	98.91x
Bespoke Extracts, Inc.	-89.6%	186.1%	190.3%	\$0.06	\$0.02	-261.9%	39.8%	-4566.2%	46.12x	115.90x
C21 Investments Inc.	-40.3%	33.3%	100.0%	\$0.40	(\$0.17)	-1209.5%	-42.9%	-2996.3%	63.81x	-148.71x
Canbiola, Inc.	68.8%	-15.9%	18.6%	N/A	N/A	-85.4%	N/A	N/A	N/A	N/A
Canopy Growth Corporation	-71.4%	-91.0%	-98.4%	\$0.44	\$0.08	-639.6%	18.5%	-1440.4%	63.70x	343.49x
Charlotte's Web Holdings, Inc.	-33.3%	-82.9%	-45.2%	\$113.66	\$24.32	-30147.5%	21.4%	-265.2%	80.96x	378.31x
CorGreen Technologies Holding	-59.7%	-60.0%	-30.8%	\$0.13	\$0.01	-116.9%	8.3%	-926.2%	89.15x	1067.97x
Corix Bioscience, Inc.	-77.3%	-87.1%	-80.5%	\$60.60	\$46.02	1101.4%	75.9%	18.2%	17.08x	22.49x
Crailar Technologies Inc.	-44.1%	-15.9%	-11.8%	\$1.95	\$1.20	80.0%	61.4%	41.0%	24.91x	40.58x
Curative Biosciences, Inc.	0.0%	0.0%	41.4%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Demand Brands, Inc.	-8.1%	-45.2%	210.1%	\$6.55	\$0.15	-1218.2%	2.3%	-186.0%	0.02x	1.02x
Earth Science Tech, Inc.	0.0%	-50.0%	0.0%	N/A	N/A	-51.8%	N/A	N/A	N/A	N/A
Elev8 Brands, Inc.	-65.9%	-8.3%	90.3%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ENDEXX Corp.	-52.3%	360.9%	213.6%	\$0.74	\$0.29	-223.6%	39.6%	-301.1%	54.50x	137.59x
Eviana Health Corporation	25.0%	-32.9%	-4.7%	\$0.13	(\$0.01)	-285.2%	-11.0%	-2166.2%	62.98x	-573.79x

Multiple year periods are calculated as the average annual return.

Comparable Public Company Market Price Metrics as of March 31, 2024

(Continued from previous page)

	2024	1 Year	2 Year	Revenues	Gross Profit	Net Income	GP Margin	NI Margin	P/Rev.	P/GP
Right On Brands, Inc.	-59.5%	-59.5%	-58.4%	\$0.16	(\$0.00)	-323.3%	-1.6%	-2047.8%	35.85x	-2300.66x
Rocky Mountain High Brands, Inc.	-50.9%	-50.9%	-50.6%	\$0.24	(\$0.24)	-1026.7%	-101.7%	-4325.4%	75.60x	-74.35x
SanSal Wellness Holdings, Inc.	N/A	N/A	N/A	\$0.81	\$0.26	-1263.8%	31.9%	-1551.2%	14.59x	45.70x
Tree of Knowledge International Corp.	-68.7%	-68.7%	38.4%	\$1.54	\$0.55	-382.4%	35.9%	-248.5%	18.72x	52.13x
True Leaf Medicine International	-56.5%	-56.5%	N/A	\$1.64	\$0.40	-315.8%	24.2%	-192.9%	16.83x	69.56x
Vitalibis, Inc.	N/A	N/A	N/A	\$0.04	\$0.02	-162.9%	52.9%	-4533.0%	1360.73x	2570.50x
Wanderport Corporation	-11.3%	-11.3%	125.8%	N/A	(\$0.02)	-16.7%	N/A	N/A	N/A	-582.53x
Western Sierra Resource Corporation	1900.0%	1900.0%	701.8%	\$0.06	\$0.02	-10.9%	30.6%	-196.1%	509.32x	1665.36x
Median of Industry Public Companies	-41.9%	-50.5%	-11.8%	\$0.59	\$0.11	-262.1%	40.1%	-370.8%	27.69x	40.58x

Median Public Companies

	3/31/24	12/31/23	9/30/23	6/30/23	3/31/23	12/31/22	9/30/22	6/30/22
Median EV/Revenue Multiple	25.35x	29.24x	16.66x	24.74x	18.23x	8.01x	8.13x	8.05x
Median EV/EBITDA Multiple	47.47x	34.88x	5.61x	30.00x	9.24x	-2.11x	6.03x	8.28x
Median Price/Earnings Multiple	36.42x	-4.62x	-5.44x	-4.15x	-2.57x	13.54x	-4.42x	-3.84x
Median EV/Gross Profit Multiple	-3.40x	34.49x	22.46x	28.77x	19.49x	14.45x	10.32x	18.66x
Median MVIC/Earnings Multiple	26.96x	42.07x	12.14x	35.34x	15.32x	-3.85x	9.88x	17.26x
Median Price/ Revenue Multiple	-4.44x	-5.50x	-5.95x	-5.05x	-3.78x	10.48x	-5.25x	-5.57x

Industry Initial Public Offerings: Hemp (dollars in millions, except share prices)

Effective Date	Company Name	Offer Price	Shares Offered	Amount Raised	Total Assets ¹	Debt ¹	LTM Revenue ¹	LTM EBITDA ¹	LTM Net Income ¹	LTM Cash Flows ¹
3/13/24	Asia Cannabis Corp.	\$0.19	12.50	\$98.22	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
1/23/24	Ovation Science Inc.	\$0.23	40.00	\$5.96	\$0.73	\$0.00	\$0.00	\$0.00	(\$0.46)	(\$0.46)
12/3/23	Charlotte's Web Holdings, Inc.	\$5.39	6.85	\$0.64	\$0.22	\$0.00	\$0.00	\$0.00	(\$0.02)	(\$0.02)
12/5/22	Elixinol Global Limited	\$0.79	6.63	\$0.75	\$0.08	\$0.00	\$0.00	\$0.00	(\$0.14)	(\$0.14)
11/18/22	Phivida Holdings Inc.	\$0.31	10.00	\$0.10	\$0.04	\$0.05	\$0.04	\$0.00	(\$0.12)	(\$0.12)
10/18/21	Creso Pharma Limited	\$0.15	0.03	\$0.00	\$0.01	\$0.05	\$0.00	(\$0.02)	(\$0.02)	(\$0.02)
8/15/21	Aja Cannafacturing, Inc.	\$0.01	2.00	\$0.02	\$0.02	\$0.00	\$0.00	\$0.00	(\$0.02)	(\$0.02)
9/16/20	Phoenix Life Sciences International Limited	\$0.01	1.00	\$0.01	\$0.01	\$0.00	\$0.00	\$0.00	(\$0.02)	(\$0.02)
9/3/20	Peak Pharmaceuticals, Inc.	\$0.10	0.41	\$0.04	\$0.01	\$0.00	\$0.00	\$0.00	(\$0.02)	(\$0.02)
	Median of all IPOs	\$0.21	6.74	\$0.37	\$0.03	\$0.00	\$0.00	\$0.00	(\$0.02)	(\$0.02)

[1] As of the effective date of the IPO

Recent Merger and Acquisition Transactions for a Majority Stake (dollars in millions)

Transaction Date	Target	Acquirer	Transaction Size	% Bought	LTM Revenues ¹	EV/ Revenues ¹	Transacti on Date	Target
3/18/24	Fresh Hemp Foods Ltd.	Tilray, Inc.	\$318.50	100.0%	N/A	N/A	N/A	N/A
1/23/24	INXL Holdings, Inc.	Khrysos Industries Inc.	\$15.14	100.0%	N/A	N/A	N/A	N/A
12/15/23	Substantially All of the Assets of Grander Distribution, LLC	TerrAscend Corp.	\$23.00	100.0%	N/A	N/A	N/A	N/A
12/17/22	Viverian	Chemesis International Inc.	\$0.50	100.0%	N/A	N/A	N/A	N/A
11/22/21	ICC Labs Inc.	Aurora Cannabis Inc.	\$219.45	100.0%	\$0.53	\$4.54	396.35x	46.60x
11/1/21	Eviana Inc.	Eviana Health Corporation	\$0.38	100.0%	N/A	N/A	N/A	N/A
10/19/20	Hemp Extraction Technology Corp.	EVITRADE Health Systems Corp.	\$6.42	100.0%	N/A	N/A	N/A	N/A
9/27/20	Pasa Verde, LLC	Nutritional High International Inc.	\$6.34	100.0%	N/A	N/A	N/A	N/A
9/16/20	Absorbent Concepts Inc.	Naturally Splendid Enterprises Ltd.	\$0.50	100.0%	\$0.84	N/A	0.59x	N/A
Median of the M&A Transaction Targets			\$1.40	100.0%	\$0.53	(\$0.02)	2.33x	-1.44x

[1] As of the close of the Transaction

■ USA ■ International

(Continued on next page)

Definitions of Financial Terms Used in this Quarterly Industry Update:

Enterprise Value (EV): Market Value of Equity + Market Value of Debt - Cash

Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA): Profitability metric sometimes also referred to as operating profit or operating earnings.

Gross Cash Flows: Net Income + Depreciation and Amortization Expense

Latest Twelve Months (LTM): Financial information is as of the latest twelve months through the date of this Quarterly Industry Update.

Market Value of Invested Capital (MVIC): Market Value of Equity + Market Value of Debt

Disclosures and Limitations: This research report is for informational and discussion purposes only. Information presented herein is not investment advice of any kind to any person and does not constitute a recommendation as to the purchase or sale of any interests or as to any other course of action. General, financial, and statistical information concerning the details of this report and related industry are from sources Cogent Valuation believes to be reliable. Cogent Valuation has accurately reflected such information in this research report; however, Cogent Valuation makes no representation as to the sources' accuracy or completeness and has accepted this information without further verification. Neither all nor any part of the content of this report may be conveyed to the public through advertising, public relations, news, sales, mail, direct transmittal, or other media without the prior written consent of Cogent Valuation. Cogent Valuation's research is as of the date reported herein. Cogent Valuation has no affiliation with any of the companies comprising the industry used as a basis for research in this report, nor does Cogent Valuation hold any investments in the companies listed herein. The content of this report may be used, in part, as a basis for any work that Cogent Valuation performs for you in the future at the sole discretion of Cogent Valuation. THIS REPORT IS NOT TO BE USED OR CONSIDERED UNDER ANY CIRCUMSTANCE BY ANYONE AS INVESTMENT ADVICE.

COGENT VALUATION is a nationally recognized full service business valuation firm that has provided independent valuation and financial advisory opinions in thousands of situations since 1991. These assignments include the valuation of companies and pass-through entities, their securities, and their intangible assets ranging in size from small, closely-held businesses and start-ups, to corporations with market values over a billion dollars, covering almost every industry and all types of transactions. With the collective backgrounds of our managing directors and professional staff, Cogent Valuation brings substantial large deal experience to bear on our middle market transaction opinions. Cogent Valuation utilizes proprietary research, intensive due diligence, and the experience and insights of its professionals to produce thoughtful, well-documented opinions that have consistently withstood the scrutiny of clients and their advisors, investors, regulators, and courts.

This industry research is provided at no charge. Further research or detailed information not covered in this report can be obtained for a fee. **Contact Steven Kam at 415-392-0888 and kam@cogentvaluation.com** for additional information or questions in connection with this research report.